Liverpool ChiroChem is proud to announce that we have been shortlisted for the prestigious UKBAA Awards in the Best Angel-VC Scale Up Investment Category.
Now in its 14th year, the annual UKBAA Angel Investment Awards celebrate high growth and success in the angel and early-stage investment market – recognising the fastest growing brands and acknowledging the founders, angels, crowd funders and early-stage venture capital investors behind them. Open to both companies and investors, these Awards seek to recognise the year’s most disruptive new market entrants and provide a definitive list of the most exciting ‘ones to watch’ in the angel and early-stage investment space.
Winners are announced at the UKBAA Investment Awards Dinner, taking place on the 19th June, in the awe-inspiring Liverpool Cathedral, which will bring together over 400 leading players from across the early-stage investment community to join in celebrations. Guests will enjoy a sparkling drinks reception, sumptuous three course dinner, guest speaker and the presentation of the awards.
If you would like to join us in toasting our success and hopefully see us be crowned the winner, please take advantage of our shortlisted rates and book here: www.eventbrite.co.uk
Syndicate Room: Video Interview with Paul Colbon
Our CEO and Co-founder Paul Colbon recently sat with SyndicateRoom to discuss the progress of Liverpool ChiroChem since our funding round on their equity investment platform in 2015. He started with a quick introduction about what we do, an overview of how our team works and a quick discussion of some of our unique selling points.
Paul then went on to discuss the ins and outs of how we have used the funds raised on SyndicateRoom, with particular focus on the R&D team in the UK, the sales & marketing team and establishing a production laboratory just outside of Shanghai in China.
He gave viewers a taster of what’s planned in the immediate future, and longer term goals for LCC. The short term will see us focus on investment into the production laboratory and the R&D team, to ensure we stay at the forefront of the drug discovery market. In the longer term, we are looking to branch out into a few different areas based on the success of our chiral technologies. Our customer base has already asked for some specific developments in this area, particularly linked with the central nervous system (CNS). We will also focus on later stage drug development.
Paul shared his experience about working with those who invested in LCC through SyndicateRoom. and how much feedback and guidance they have offered on the business development and commercial side of the business. Paul hinted that to ensure production can be scaled up, and in order accelerate the growth of the company, a further funding round will be needed in the future.
Hear from Paul himself, and watch the entire video below:
The Climbing Chemists:
Great to see Sam, Ilaria and Joe having fun.
A big thanks to Joe for starting the 'climbing revolution' at LCC.
Liverpool Spin-Out Heading for the Top
Dr Paul Colbon, CEO of Liverpool ChiroChem Ltd (LCC) was interviewed by Technology Networks. In this interview, Dr Paul Colbon, describes how he and Dr Jianjun Wu and Dr Jiwu Ruan have formed an international chemical company that develops chiral chemicals for the drug discovery market, by spinning-out technology Dr Wu developed at the University of Liverpool.
View full press release.
Liverpool ChiroChem is pleased to announce the appointment of Dr Stephen Parker as Non-executive Chairman of the company
The appointment of Dr Parker marks a new growth phase for Liverpool ChiroChem as it broadens its capabilities across drug discovery, development and manufacturing services, with a growing team of PhD chemists at our R&D centre along with an expanding production laboratory in China.
Dr Parker has enjoyed a career spanning over 30 years in the healthcare and pharma sector working both within private and public business. He is currently non-executive Chairman of AIM Listed companies Silence Therapeutics plc and Sareum Holdings Plc and was formerly a partner in the Celtic Pharma funds and Chief Financial Officer at Oxford GlycoSciences. In addition, he has extensive corporate finance experience having been an investment banker focusing on pharma and biotechnology with Barings, Warburg and Apax Partners, where he advised leading chiral science company ChiroScience plc.
View full press release.
LCC wins the Bionow startup company of the year award.
LCC wins 1st prize at the Merseyside Innovation Awards.